| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Exelixis |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Taiho Pharmaceutical |
| Recipient: You |
| Company: Autem therapeutics |
| Recipient: You |
| Company: Arcus therapeutics |
| Recipient: You |
| Company: Xilio therapeutics |
| Recipient: You |
| Company: Astellas Pharma |
| Recipient: You |
| Company: Autem Therapeutics |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Replimune |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: AstraZeneca/MedImmune |
| Recipient: Your Institution |
| Company: Exelixis |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Clovis Oncology |
| Recipient: Your Institution |
| Company: Merck Sharp & Dohme |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: Actuate Therapeutics |
| Recipient: Your Institution |
| Company: Daiichi Sankyo/UCB Japan |
| Recipient: Your Institution |
| Company: KAHR Medical |
| Recipient: Your Institution |
| Company: innovent biologics |
| Recipient: Your Institution |
| Company: Arcus therapeutics |
| Recipient: Your Institution |
| Company: Oxford biotherapeutics |
| Recipient: Your Institution |
| Company: Incyte Corporation |
| Recipient: Your Institution |
| Company: Replimune |
| Recipient: Your Institution |
| Company: Phanes Therapeutics |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|